4.7 Article

Discovery of a Potent, Selective, and Cell-Active Dual Inhibitor of Protein Arginine Methyltransferase 4 and Protein Arginine Methyltransferase 6

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 59, 期 19, 页码 9124-9139

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.6b01033

关键词

-

资金

  1. U.S. National Institutes of Health [R01GM103893]
  2. AbbVie [1097737]
  3. Bayer Pharma AG
  4. Boehringer Ingelheim
  5. Canada Foundation for Innovation
  6. Eshelman Institute for Innovation
  7. Genome Canada
  8. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD Grant] [115766]
  9. Janssen
  10. Merck Co.
  11. Novartis Pharma AG
  12. Ontario Ministry of Economic Development and Innovation
  13. Pfizer
  14. Sao Paulo Research Foundation-FAPESP
  15. Takeda
  16. Wellcome Trust
  17. National Institute of Mental Health's Psychoactive Drug Screening Program [HHSN-271-2013-00017-C]
  18. SGC

向作者/读者索取更多资源

Well-characterized selective inhibitors of protein arginine methyltransferases (PRMTs) are invaluable chemical tools for testing biological and therapeutic hypotheses. Based on 4, a fragment-like inhibitor of type I PRMTs, we conducted structure activity relationship (SAR) studies and explored three regions of this scaffold. The studies led to the discovery of a potent, selective, and cell-active dual inhibitor of PRMT4 and PRMT6, 17 (MS049). As compared to 4, 17 displayed much improved potency for PRMT4 and PRMT6 in both biochemical and cellular assays. It was selective for PRMT4 and PRMT6 over other PRMTs and a broad range of other epigenetic modifiers and nonepigenetic targets. We also developed 46 (MS049N), which was inactive in biochemical and cellular assays, as a negative control for chemical biology studies. Considering possible overlapping substrate specificity of PRMTs, 17 and 46 are valuable chemical tools for dissecting specific biological functions and dysregulation of PRMT4 and PRMT6 in health and disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据